Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company reports corporate governance changes effective for the 2017 Annual Meeting of Stockholders. The report date is December 19, 2016, with the signature date of December 21, 2016.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Board Departure: Lamberto Andreotti notified the Company on December 19, 2016, that he will not stand for re-election to the Board of Directors at the 2017 Annual Meeting.
- Leadership Election: On December 21, 2016, the Board elected Giovanni Caforio, M.D., the current Chief Executive Officer, to become Chairman of the Board effective May 2, 2017.
- Role Consolidation: Dr. Caforio will serve in the dual capacity of Chairman of the Board and Chief Executive Officer.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, management commentary on operations, or specific risk factors. The primary focus is the transition of board leadership.
Investor Verification Checklist
- Verify the exact date of the 2017 Annual Meeting of Stockholders (expected May 2, 2017).
- Confirm the official press release (Exhibit 99.1) regarding the retirement of Lamberto Andreotti and the election of Giovanni Caforio.
- Review the Company's proxy statement for the 2017 Annual Meeting for details on the new board composition.